Compare Mercadolibre Inc (MELI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Mercadolibre Inc trades at $1,838.94 (market cap $98.35B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Mercadolibre Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| MELI | XBI | |
|---|---|---|
Market Cap | $98.35B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $2.51K | $164.28 |
52-Week Low | $1.55K | $86.92 |
Enterprise Value | $106.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,828.29, up 0.22% with strong technical bullish signals from moving averages. The company demonstrates exceptional revenue growth, reaching $28.89 billion in 2025, though recent earnings misses and margin pressures from strategic investments have tempered investor enthusiasm. Analyst consensus remains strongly bullish with a $2,150 price target, representing 17.6% upside potential from current levels.
MELI's growth-first strategy is driving market share gains but sacrificing near-term profitability. The stock presents a compelling opportunity for long-term investors willing to tolerate margin volatility, though execution risks and competitive pressures in Latin American e-commerce warrant careful monitoring. Current valuation at 52.77 P/E reflects premium pricing for high-growth expectations.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
